Aurovir Pharma Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Angel
- Investors
-
1
Aurovir Pharma General Information
Description
Developer of gold-ion-based inhaled therapies designed for the treatment of pulmonary disorders. The company utilizes aurothioglucose and a proprietary formulation process to deliver gold ions directly to the lungs, enabling healthcare providers to treat viral infections, inflammatory diseases, and lung cancer through targeted protein interaction and extended on-target half-life.
Contact Information
Website
www.aurovir-pharma.comCorporate Office
- Riglergasse 4
- Vienna, Vienna 1180
- Austria
Corporate Office
- Riglergasse 4
- Vienna, Vienna 1180
- Austria
Aurovir Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Angel (individual) | 01-Jun-2025 | Completed | Generating Revenue |
Aurovir Pharma Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Startup Angels Alb-Bodensee | Angel Group | Minority |
Aurovir Pharma FAQs
-
When was Aurovir Pharma founded?
Aurovir Pharma was founded in 2023.
-
Where is Aurovir Pharma headquartered?
Aurovir Pharma is headquartered in Vienna, Austria.
-
What industry is Aurovir Pharma in?
Aurovir Pharma’s primary industry is Drug Discovery.
-
Is Aurovir Pharma a private or public company?
Aurovir Pharma is a Private company.
-
What is Aurovir Pharma’s current revenue?
The current revenue for Aurovir Pharma is .
-
Who are Aurovir Pharma’s investors?
Startup Angels Alb-Bodensee has invested in Aurovir Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process